CSF1R and Alexander disease: In this study, the role of macrophage lineage cells as well as their potential as therapeutic targets for AxD were examined by treating GfapR236H/+ AxD model mice with the CSF1R inhibitor pexidartinib (formerly PLX3397, Plexxikon Inc.), which was recently approved by the FDA for treatment of tenosynovial giant cell tumors.